Leo Pharma wins Japanese approval to launch and manufacture main asset
Adtralza, an atopic dermatitis treatment, may now be made and marketed in Japan, marking a milestone in the Danish pharmaceutical firm’s global strategy.
by ulrich quistgaard, translated by daniel pedersen
Japan Ministry of Health, Labor and Welfare has approved Leo Pharma’s launch of Adtralza (tralokinumab), a treatment for adults with atopic dermatitis, the Danish pharmaceutical firm announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma reaches endpoints in phase III hand eczema trial
For subscribers
